CoChat

Patients with Primary Immunodeficiencies Are a Reservoir of Poliovirus and a Risk to Polio Eradication

Open access
Aghamohammadi, Asghar, Abolhassani, Hassan, Kutukculer, Necil, Wassilak, Steve G., Pallansch, Mark A., Kluglein, Samantha, Quinn, Jessica, Sutter, Roland W., Wang, Xiaochuan, Sanal, Ozden, Latysheva, Tatiana, Ikinciogullari, Aydan, Bernatowska, Ewa, Tuzankina, Irina A., Costa-Carvalho, Beatriz T., Franco, Jose Luis, Somech, Raz, Karakoc-Aydiner, Elif, Singh, Surjit, Bezrodnik, Liliana, Espinosa-Rosales, Francisco J., Shcherbina, Anna, Lau, Yu-Lung, Nonoyama, Shigeaki, Modell, Fred, Modell, Vicki, The JMF Centers Network Investigators and Study Collaborators, Barbouche, Mohamed-Ridha, McKinlay, Mark A. · 2017 · Frontiers in Immunology
Cited by 54

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Immunodeficiency-associated vaccine-derived polioviruses (iVDPVs) have been isolated from primary immunodeficiency (PID) patients exposed to oral poliovirus vaccine (OPV). Patients may excrete poliovirus strains for months or years; the excreted viruses are frequently highly divergent from the parental OPV and have been shown to be as neurovirulent as wild virus. Thus, these patients represent a potential reservoir for transmission of neurovirulent polioviruses in the post-eradication era. In support of WHO recommendations to better estimate the prevalence of poliovirus excreters among PIDs and characterize genetic evolution of these strains, 635 patients including 570 with primary antibody deficiencies and 65 combined immunodeficiencies were studied from 13 OPV-using countries. Two stool samples were collected over 4 days, tested for enterovirus, and the poliovirus positive samples were sequenced. Thirteen patients (2%) excreted polioviruses, most for less than 2 months following identification of infection. Five (0.8%) were classified as iVDPVs (only in combined immunodeficiencies and mostly poliovirus serotype 2). Non-polio enteroviruses were detected in 30 patients (4.7%). Patients with combined immunodeficiencies had increased risk of delayed poliovirus clearance compared to primary antibody deficiencies. Usually, iVDPV was detected in subjects with combined immunodeficiencies in a short period of time after OPV exposure, most for less than 6 months. Surveillance for poliovirus excretion among PID patients should be reinforced until polio eradication is certified and the use of OPV is stopped. Survival rates among PID patients are improving in lower and middle income countries, and iVDPV excreters are identified more frequently. Antivirals or enhanced immunotherapies presently in development represent the only potential means to manage the treatment of prolonged excreters and the risk they present to the polio endgame.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2017.00685

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 54

Metadata

Authors
Aghamohammadi, A., Abolhassani, H., Kutukculer, N., Wassilak, S. G., Pallansch, M. A., Kluglein, S., Quinn, J., Sutter, R. W., Wang, X., Sanal, O., Latysheva, T., Ikinciogullari, A., Bernatowska, E., Tuzankina, I. A., Costa-Carvalho, B. T., Franco, J. L., Somech, R., Karakoc-Aydiner, E., Singh, S., Bezrodnik, L., Espinosa-Rosales, F. J., Shcherbina, A., Lau, Y.-L., Nonoyama, S., Modell, F., Modell, V., The JMF Centers Network Investigators and Study Collaborators, Barbouche, M.-R., & McKinlay, M. A.
Venue
Frontiers in Immunology
Published
2017-06-13
Volume
8
Pages
685-685
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2726731258
Cited by
54
References
4
FWCI
5.07
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.